JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
Strokes are affecting approximately 1.8 million people annually
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
Subscribe To Our Newsletter & Stay Updated
